Personalized Medicine Accounting

Personalized Medicine Accounting: Financial Reporting for Tailored Healthcare

Treatments

Introduction

Personalized medicine refers to medical decision-making tailored to individual patient

characteristics diagnosed through genomic and molecular analysis. By integrating genomics,

clinical trials, big data and custom diagnostics, personalized medicine aims to optimize

treatment effectiveness for each patient. As these approaches mature, accounting standards

must address financial reporting implications.

This paper examines key accounting issues in personalized medicine and proposes principles

Advances in Genomic Technologies

Rapid advancements in genomic sequencing, molecular diagnostics, and computational

analysis have enabled emerging personalized medicine approaches:

- Late 1990s: Successful mapping of the human genome provided the foundation for

molecular medicine applications.

- 2008: Next-generation DNA sequencing technologies launched, reducing sequencing costs

exponentially to enable clinical applications.

- 2013: FDA approved first cancer drug targeting a specific gene mutation, establishing the

approval pathway for molecularly targeted therapies.

- 2015: Launch of large biobanks and datasets like UK Biobank enabled discovery of disease

Accounting Challenges in Personalized Medicine

Several challenges arise in applying traditional frameworks to personalized medical

innovations:

Research and Development Costing

Genomic, computational and clinical research expenditures require new cost accounting as

multi-component, digital-enabled efforts yield diverse molecularly defined products/services.

Revenue Recognition

Unique business models emerge via clinical genomic profiling, computational platforms, and

on-going care management necessitating flexible recognition approaches.

Valuation of Molecular Innovations

Genomic/omic biomarkers, diagnostic algorithms and targeted therapies represent intangible

innovations valued differently than traditional products requiring specialized metrics.

1. Molecular R&D Cost Accounting

- Separately track qualifying discovery, clinical, computational and digital infrastructure

costs for intangible portfolio components.

- Apply activity-based or portfolio approaches proportionately recognizing multi-

component research spanning discovery to clinical adoption.

2. Revenue Recognition for Personalized Offerings

- Employ milestone-based or subscription recognition of genomic profiling, digital platform

access and on-going clinical management services.

- Provide transparency distinguishing recurring from one-time revenue streams to capture

value over time.

- Incorporate costs, probabilities and timing of milestones through discounted cash flow or

real options analyses.

4. Disclosures for Regulatory Approval Uncertainties

- Clearly discuss evolving regulations around data, clinical trials and approvals for novel

diagnostics and precision therapies.

- Quantify estimated costs of compliance scenarios and sensitivity of valuations to potential

regulatory outcomes.

- Track clinical and economic outcomes transparently comparing personalized therapies to

emerging field.

Operationalizing Principles for Personalized Medicine Accounting

activities across personalized medicine's value chain:

1. Initialize Molecular Discovery Portfolio

- Configure intangible asset ledgers to track qualifying genomic, clinical and computational

research investments.

2. Progress Molecular Projects

- Apply activity-based or portfolio costing approaches to recognize multi-year, multi-

component R&D expenditures.

- Capture regulatory and clinical trial milestones via intangible asset valuation contingent

4. Commence Commercialization

5. Monitor Clinical Outcomes

- Benchmark treatment effectiveness transparently comparing outcomes and costs to

alternatives where available.

6. Periodically Review Guidance

- Revisit assumptions, costs and valuations at predefined intervals or as regulatory/clinical

evidence and applications evolve.

Overall, this framework systematically incorporates stratified medicine activities into

financial reports through consistently applied yet adaptively refined accounting principles.

stakeholders to refine guidance supporting responsible innovation aligned with patient

interests. Overall, evolving standards balances oversight with unlocking personalized

medicine’s full potential for improving human welfare.

characteristics diagnosed through genomic and molecular analysis. By integrating genomics,

clinical trials, big data and custom diagnostics, personalized medicine aims to optimize

treatment effectiveness for each patient. As these approaches mature, accounting standards

must address financial reporting implications.

This paper examines key accounting issues in personalized medicine and proposes principles

for capturing its value. The first section provides background on emerging genomic

technologies enabling personalized strategies. Challenges involving research and

development costing, revenue recognition, and valuation are then discussed. Drawing from

these factors, an accounting framework is proposed for systematically incorporating

supporting continued innovation responsibly.

- Late 1990s: Successful mapping of the human genome provided the foundation for

molecular medicine applications.

- 2008: Next-generation DNA sequencing technologies launched, reducing sequencing costs

exponentially to enable clinical applications.

- 2013: FDA approved first cancer drug targeting a specific gene mutation, establishing the

approval pathway for molecularly targeted therapies.

- 2015: Launch of large biobanks and datasets like UK Biobank enabled discovery of disease

subtypes and drug response biomarkers at population scale.

advanced cancers, achieving superior outcomes to one-size-fits-all chemotherapy.

Several challenges arise in applying traditional frameworks to personalized medical

innovations:

Research and Development Costing

multi-component, digital-enabled efforts yield diverse molecularly defined products/services.

Revenue Recognition

Unique business models emerge via clinical genomic profiling, computational platforms, and

on-going care management necessitating flexible recognition approaches.

Valuation of Molecular Innovations

Genomic/omic biomarkers, diagnostic algorithms and targeted therapies represent intangible

innovations valued differently than traditional products requiring specialized metrics.

Regulatory Compliance

introduce uncertainties necessitating scenario-based financial planning.

- Separately track qualifying discovery, clinical, computational and digital infrastructure

costs for intangible portfolio components.

- Apply activity-based or portfolio approaches proportionately recognizing multi-

component research spanning discovery to clinical adoption.

2. Revenue Recognition for Personalized Offerings

- Employ milestone-based or subscription recognition of genomic profiling, digital platform

access and on-going clinical management services.

value over time.

4. Disclosures for Regulatory Approval Uncertainties

- Clearly discuss evolving regulations around data, clinical trials and approvals for novel

diagnostics and precision therapies.

- Quantify estimated costs of compliance scenarios and sensitivity of valuations to potential

regulatory outcomes.

5. Treatment Effectiveness Benchmarking

- Track clinical and economic outcomes transparently comparing personalized therapies to

alternative standards where available.

- Periodically benchmark against evolving evidence on treatment effectiveness and cost-

effectiveness.

medicines, accounting promotes transparency and responsibly paced innovation in this

Operationalizing Principles for Personalized Medicine Accounting

1. Initialize Molecular Discovery Portfolio

- Configure intangible asset ledgers to track qualifying genomic, clinical and computational

research investments.

2. Progress Molecular Projects

- Apply activity-based or portfolio costing approaches to recognize multi-year, multi-

component R&D expenditures.

3. Validate Technologies and Products

- Capture regulatory and clinical trial milestones via intangible asset valuation contingent

on future adoption/partnerships.

4. Commence Commercialization

6. Periodically Review Guidance

- Revisit assumptions, costs and valuations at predefined intervals or as regulatory/clinical

evidence and applications evolve.

financial reports through consistently applied yet adaptively refined accounting principles.

Conclusion

As genomic and data technologies transform healthcare delivery, accounting standards must

evolve to transparently capture the value of molecular innovations. This paper analyzes

financial reporting challenges arising from personalized medicine’s intangible R&D focus,

dynamic business models and regulatory uncertainties.

To systematically address these, new principles and an operational accounting framework

stakeholders to refine guidance supporting responsible innovation aligned with patient

treatment effectiveness for each patient. As these approaches mature, accounting standards

must address financial reporting implications.

This paper examines key accounting issues in personalized medicine and proposes principles

for capturing its value. The first section provides background on emerging genomic

technologies enabling personalized strategies. Challenges involving research and

development costing, revenue recognition, and valuation are then discussed. Drawing from

these factors, an accounting framework is proposed for systematically incorporating

personalized treatments. The conclusion reflects on open areas and calls for standards

supporting continued innovation responsibly.

Advances in Genomic Technologies

Rapid advancements in genomic sequencing, molecular diagnostics, and computational

- 2013: FDA approved first cancer drug targeting a specific gene mutation, establishing the

approval pathway for molecularly targeted therapies.

subtypes and drug response biomarkers at population scale.

- 2020: Precision oncology guided by genomic profiling became standard of care for many

advanced cancers, achieving superior outcomes to one-size-fits-all chemotherapy.

These technical milestones transformed medicine by correlating genetics to drug responses at

individual levels, supporting tailored prevention and treatment strategies. Their accounting

requires consideration.

Accounting Challenges in Personalized Medicine

Several challenges arise in applying traditional frameworks to personalized medical

Research and Development Costing

Unique business models emerge via clinical genomic profiling, computational platforms, and

on-going care management necessitating flexible recognition approaches.

Valuation of Molecular Innovations

Genomic/omic biomarkers, diagnostic algorithms and targeted therapies represent intangible

innovations valued differently than traditional products requiring specialized metrics.

Regulatory Compliance

Evolving regulations around clinical trials, diagnostic approval pathways, and data privacy

introduce uncertainties necessitating scenario-based financial planning.

The following section proposes accounting principles addressing these factors systematically

- Apply activity-based or portfolio approaches proportionately recognizing multi-

component research spanning discovery to clinical adoption.

- Employ milestone-based or subscription recognition of genomic profiling, digital platform

access and on-going clinical management services.

- Provide transparency distinguishing recurring from one-time revenue streams to capture

value over time.

3. Valuation of Molecular Innovations

- Value intangible portfolio components based on potential for clinical adoption and

economic benefits contingent on partnerships and regulatory approvals.

real options analyses.

- Clearly discuss evolving regulations around data, clinical trials and approvals for novel

regulatory outcomes.

The following section proposes accounting principles addressing these factors systematically

for transparent personalized medicine reporting.

Proposed Accounting Principles

1. Molecular R&D Cost Accounting

- Separately track qualifying discovery, clinical, computational and digital infrastructure

costs for intangible portfolio components.

- Apply activity-based or portfolio approaches proportionately recognizing multi-

3. Valuation of Molecular Innovations

- Value intangible portfolio components based on potential for clinical adoption and

economic benefits contingent on partnerships and regulatory approvals.

real options analyses.

4. Disclosures for Regulatory Approval Uncertainties

- Clearly discuss evolving regulations around data, clinical trials and approvals for novel

diagnostics and precision therapies.

- Quantify estimated costs of compliance scenarios and sensitivity of valuations to potential

regulatory outcomes.

5. Treatment Effectiveness Benchmarking

alternative standards where available.

effectiveness.

emerging field.

Operationalizing Principles for Personalized Medicine Accounting

To operationalize the above principles, the following framework is proposed for accounting

activities across personalized medicine's value chain:

1. Initialize Molecular Discovery Portfolio

- Configure intangible asset ledgers to track qualifying genomic, clinical and computational

research investments.

2. Progress Molecular Projects

component R&D expenditures.

management income streams.

5. Monitor Clinical Outcomes

- Benchmark treatment effectiveness transparently comparing outcomes and costs to

6. Periodically Review Guidance

- Revisit assumptions, costs and valuations at predefined intervals or as regulatory/clinical

evidence and applications evolve.

Overall, this framework systematically incorporates stratified medicine activities into

financial reports through consistently applied yet adaptively refined accounting principles.

Conclusion

evolve to transparently capture the value of molecular innovations. This paper analyzes

interests. Overall, evolving standards balances oversight with unlocking personalized

medicine’s full potential for improving human welfare.

Personalized medicine refers to medical decision-making tailored to individual patient

characteristics diagnosed through genomic and molecular analysis. By integrating genomics,

clinical trials, big data and custom diagnostics, personalized medicine aims to optimize

treatment effectiveness for each patient. As these approaches mature, accounting standards

must address financial reporting implications.

This paper examines key accounting issues in personalized medicine and proposes principles

for capturing its value. The first section provides background on emerging genomic

technologies enabling personalized strategies. Challenges involving research and

these factors, an accounting framework is proposed for systematically incorporating

- Late 1990s: Successful mapping of the human genome provided the foundation for

molecular medicine applications.

exponentially to enable clinical applications.

- 2013: FDA approved first cancer drug targeting a specific gene mutation, establishing the

approval pathway for molecularly targeted therapies.

- 2015: Launch of large biobanks and datasets like UK Biobank enabled discovery of disease

subtypes and drug response biomarkers at population scale.

- 2020: Precision oncology guided by genomic profiling became standard of care for many

advanced cancers, achieving superior outcomes to one-size-fits-all chemotherapy.

These technical milestones transformed medicine by correlating genetics to drug responses at

innovations:

Research and Development Costing

Genomic, computational and clinical research expenditures require new cost accounting as

multi-component, digital-enabled efforts yield diverse molecularly defined products/services.

Revenue Recognition

Unique business models emerge via clinical genomic profiling, computational platforms, and

on-going care management necessitating flexible recognition approaches.

Valuation of Molecular Innovations

Genomic/omic biomarkers, diagnostic algorithms and targeted therapies represent intangible

innovations valued differently than traditional products requiring specialized metrics.

Regulatory Compliance

Evolving regulations around clinical trials, diagnostic approval pathways, and data privacy

introduce uncertainties necessitating scenario-based financial planning.

Proposed Accounting Principles

- Separately track qualifying discovery, clinical, computational and digital infrastructure

- Apply activity-based or portfolio approaches proportionately recognizing multi-

component research spanning discovery to clinical adoption.

2. Revenue Recognition for Personalized Offerings

- Employ milestone-based or subscription recognition of genomic profiling, digital platform

access and on-going clinical management services.

- Provide transparency distinguishing recurring from one-time revenue streams to capture

value over time.

- Value intangible portfolio components based on potential for clinical adoption and

economic benefits contingent on partnerships and regulatory approvals.

- Clearly discuss evolving regulations around data, clinical trials and approvals for novel

diagnostics and precision therapies.

- Quantify estimated costs of compliance scenarios and sensitivity of valuations to potential

regulatory outcomes.

5. Treatment Effectiveness Benchmarking

- Track clinical and economic outcomes transparently comparing personalized therapies to

alternative standards where available.

effectiveness.

To operationalize the above principles, the following framework is proposed for accounting

activities across personalized medicine's value chain:

1. Initialize Molecular Discovery Portfolio

research investments.

2. Progress Molecular Projects

- Apply activity-based or portfolio costing approaches to recognize multi-year, multi-

component R&D expenditures.

3. Validate Technologies and Products

- Capture regulatory and clinical trial milestones via intangible asset valuation contingent

on future adoption/partnerships.

- Employ flexible recognition of recurring profiling revenues and on-going patient

5. Monitor Clinical Outcomes

6. Periodically Review Guidance

- Revisit assumptions, costs and valuations at predefined intervals or as regulatory/clinical

evidence and applications evolve.

Overall, this framework systematically incorporates stratified medicine activities into

financial reports through consistently applied yet adaptively refined accounting principles.

Conclusion

As genomic and data technologies transform healthcare delivery, accounting standards must

evolve to transparently capture the value of molecular innovations. This paper analyzes

dynamic business models and regulatory uncertainties.

Personalized medicine refers to medical decision-making tailored to individual patient

characteristics diagnosed through genomic and molecular analysis. By integrating genomics,

clinical trials, big data and custom diagnostics, personalized medicine aims to optimize

treatment effectiveness for each patient. As these approaches mature, accounting standards

This paper examines key accounting issues in personalized medicine and proposes principles

for capturing its value. The first section provides background on emerging genomic

technologies enabling personalized strategies. Challenges involving research and

development costing, revenue recognition, and valuation are then discussed. Drawing from

these factors, an accounting framework is proposed for systematically incorporating

personalized treatments. The conclusion reflects on open areas and calls for standards

supporting continued innovation responsibly.

Advances in Genomic Technologies

Rapid advancements in genomic sequencing, molecular diagnostics, and computational

- Late 1990s: Successful mapping of the human genome provided the foundation for

exponentially to enable clinical applications.

- 2013: FDA approved first cancer drug targeting a specific gene mutation, establishing the

approval pathway for molecularly targeted therapies.

- 2015: Launch of large biobanks and datasets like UK Biobank enabled discovery of disease

subtypes and drug response biomarkers at population scale.

- 2020: Precision oncology guided by genomic profiling became standard of care for many

advanced cancers, achieving superior outcomes to one-size-fits-all chemotherapy.

These technical milestones transformed medicine by correlating genetics to drug responses at

requires consideration.

Genomic, computational and clinical research expenditures require new cost accounting as

multi-component, digital-enabled efforts yield diverse molecularly defined products/services.

Revenue Recognition

on-going care management necessitating flexible recognition approaches.

Valuation of Molecular Innovations

Genomic/omic biomarkers, diagnostic algorithms and targeted therapies represent intangible

innovations valued differently than traditional products requiring specialized metrics.

Regulatory Compliance

Evolving regulations around clinical trials, diagnostic approval pathways, and data privacy

introduce uncertainties necessitating scenario-based financial planning.

The following section proposes accounting principles addressing these factors systematically

Proposed Accounting Principles

- Apply activity-based or portfolio approaches proportionately recognizing multi-

component research spanning discovery to clinical adoption.

2. Revenue Recognition for Personalized Offerings

- Employ milestone-based or subscription recognition of genomic profiling, digital platform

access and on-going clinical management services.

- Provide transparency distinguishing recurring from one-time revenue streams to capture

value over time.

- Value intangible portfolio components based on potential for clinical adoption and

diagnostics and precision therapies.

- Quantify estimated costs of compliance scenarios and sensitivity of valuations to potential

regulatory outcomes.

5. Treatment Effectiveness Benchmarking

- Track clinical and economic outcomes transparently comparing personalized therapies to

alternative standards where available.

- Periodically benchmark against evolving evidence on treatment effectiveness and cost-

effectiveness.

By standardizing principles to systematically track value creation stages for stratified

medicines, accounting promotes transparency and responsibly paced innovation in this

emerging field.

Operationalizing Principles for Personalized Medicine Accounting

activities across personalized medicine's value chain:

research investments.

2. Progress Molecular Projects

- Apply activity-based or portfolio costing approaches to recognize multi-year, multi-

component R&D expenditures.

3. Validate Technologies and Products

- Capture regulatory and clinical trial milestones via intangible asset valuation contingent

on future adoption/partnerships.

4. Commence Commercialization

- Employ flexible recognition of recurring profiling revenues and on-going patient

Overall, this framework systematically incorporates stratified medicine activities into

financial reports through consistently applied yet adaptively refined accounting principles.

As genomic and data technologies transform healthcare delivery, accounting standards must

evolve to transparently capture the value of molecular innovations. This paper analyzes

financial reporting challenges arising from personalized medicine’s intangible R&D focus,

dynamic business models and regulatory uncertainties.

To systematically address these, new principles and an operational accounting framework

have been proposed. Continued advancement relies on accounting proactively engaging

stakeholders to refine guidance supporting responsible innovation aligned with patient

interests. Overall, evolving standards balances oversight with unlocking personalized

clinical trials, big data and custom diagnostics, personalized medicine aims to optimize

This paper examines key accounting issues in personalized medicine and proposes principles

for capturing its value. The first section provides background on emerging genomic

technologies enabling personalized strategies. Challenges involving research and

development costing, revenue recognition, and valuation are then discussed. Drawing from

these factors, an accounting framework is proposed for systematically incorporating

personalized treatments. The conclusion reflects on open areas and calls for standards

supporting continued innovation responsibly.

Advances in Genomic Technologies

Rapid advancements in genomic sequencing, molecular diagnostics, and computational

analysis have enabled emerging personalized medicine approaches:

- Late 1990s: Successful mapping of the human genome provided the foundation for

- 2015: Launch of large biobanks and datasets like UK Biobank enabled discovery of disease

subtypes and drug response biomarkers at population scale.

advanced cancers, achieving superior outcomes to one-size-fits-all chemotherapy.

These technical milestones transformed medicine by correlating genetics to drug responses at

individual levels, supporting tailored prevention and treatment strategies. Their accounting

requires consideration.

Accounting Challenges in Personalized Medicine

Several challenges arise in applying traditional frameworks to personalized medical

innovations:

Research and Development Costing

Rapid advancements in genomic sequencing, molecular diagnostics, and computational

analysis have enabled emerging personalized medicine approaches:

- Late 1990s: Successful mapping of the human genome provided the foundation for

molecular medicine applications.

- 2008: Next-generation DNA sequencing technologies launched, reducing sequencing costs

exponentially to enable clinical applications.

- 2013: FDA approved first cancer drug targeting a specific gene mutation, establishing the

individual levels, supporting tailored prevention and treatment strategies. Their accounting

requires consideration.

Accounting Challenges in Personalized Medicine

Several challenges arise in applying traditional frameworks to personalized medical

innovations:

Research and Development Costing

Genomic, computational and clinical research expenditures require new cost accounting as

multi-component, digital-enabled efforts yield diverse molecularly defined products/services.

Revenue Recognition

Unique business models emerge via clinical genomic profiling, computational platforms, and

on-going care management necessitating flexible recognition approaches.

Genomic/omic biomarkers, diagnostic algorithms and targeted therapies represent intangible

innovations valued differently than traditional products requiring specialized metrics.

The following section proposes accounting principles addressing these factors systematically

for transparent personalized medicine reporting.

Proposed Accounting Principles

1. Molecular R&D Cost Accounting

- Separately track qualifying discovery, clinical, computational and digital infrastructure

costs for intangible portfolio components.

- Apply activity-based or portfolio approaches proportionately recognizing multi-

3. Valuation of Molecular Innovations

- Value intangible portfolio components based on potential for clinical adoption and

economic benefits contingent on partnerships and regulatory approvals.

real options analyses.

4. Disclosures for Regulatory Approval Uncertainties

- Clearly discuss evolving regulations around data, clinical trials and approvals for novel

diagnostics and precision therapies.

- Quantify estimated costs of compliance scenarios and sensitivity of valuations to potential

regulatory outcomes.

5. Treatment Effectiveness Benchmarking

alternative standards where available.

effectiveness.

emerging field.

Operationalizing Principles for Personalized Medicine Accounting

To operationalize the above principles, the following framework is proposed for accounting

activities across personalized medicine's value chain:

1. Initialize Molecular Discovery Portfolio

- Configure intangible asset ledgers to track qualifying genomic, clinical and computational

research investments.

2. Progress Molecular Projects

component R&D expenditures.

management income streams.

5. Monitor Clinical Outcomes

- Benchmark treatment effectiveness transparently comparing outcomes and costs to

6. Periodically Review Guidance

- Revisit assumptions, costs and valuations at predefined intervals or as regulatory/clinical

evidence and applications evolve.

Overall, this framework systematically incorporates stratified medicine activities into

financial reports through consistently applied yet adaptively refined accounting principles.

Conclusion

evolve to transparently capture the value of molecular innovations. This paper analyzes

interests. Overall, evolving standards balances oversight with unlocking personalized

medicine’s full potential for improving human welfare.

Personalized medicine refers to medical decision-making tailored to individual patient

characteristics diagnosed through genomic and molecular analysis. By integrating genomics,

clinical trials, big data and custom diagnostics, personalized medicine aims to optimize

treatment effectiveness for each patient. As these approaches mature, accounting standards

must address financial reporting implications.

This paper examines key accounting issues in personalized medicine and proposes principles

for capturing its value. The first section provides background on emerging genomic

technologies enabling personalized strategies. Challenges involving research and

these factors, an accounting framework is proposed for systematically incorporating

- Late 1990s: Successful mapping of the human genome provided the foundation for

molecular medicine applications.

exponentially to enable clinical applications.

- 2013: FDA approved first cancer drug targeting a specific gene mutation, establishing the

approval pathway for molecularly targeted therapies.

- 2015: Launch of large biobanks and datasets like UK Biobank enabled discovery of disease

subtypes and drug response biomarkers at population scale.

- 2020: Precision oncology guided by genomic profiling became standard of care for many

advanced cancers, achieving superior outcomes to one-size-fits-all chemotherapy.

These technical milestones transformed medicine by correlating genetics to drug responses at

innovations:

Research and Development Costing

Genomic, computational and clinical research expenditures require new cost accounting as

multi-component, digital-enabled efforts yield diverse molecularly defined products/services.

Revenue Recognition

Unique business models emerge via clinical genomic profiling, computational platforms, and

on-going care management necessitating flexible recognition approaches.

Valuation of Molecular Innovations

Genomic/omic biomarkers, diagnostic algorithms and targeted therapies represent intangible

innovations valued differently than traditional products requiring specialized metrics.

Regulatory Compliance

Evolving regulations around clinical trials, diagnostic approval pathways, and data privacy

introduce uncertainties necessitating scenario-based financial planning.

Proposed Accounting Principles

- Separately track qualifying discovery, clinical, computational and digital infrastructure

- Apply activity-based or portfolio approaches proportionately recognizing multi-

component research spanning discovery to clinical adoption.

2. Revenue Recognition for Personalized Offerings

- Employ milestone-based or subscription recognition of genomic profiling, digital platform

access and on-going clinical management services.

- Provide transparency distinguishing recurring from one-time revenue streams to capture

value over time.

- Value intangible portfolio components based on potential for clinical adoption and

economic benefits contingent on partnerships and regulatory approvals.

- Clearly discuss evolving regulations around data, clinical trials and approvals for novel

diagnostics and precision therapies.

- Quantify estimated costs of compliance scenarios and sensitivity of valuations to potential

regulatory outcomes.

5. Treatment Effectiveness Benchmarking

- Track clinical and economic outcomes transparently comparing personalized therapies to

alternative standards where available.

effectiveness.

To operationalize the above principles, the following framework is proposed for accounting

activities across personalized medicine's value chain:

1. Initialize Molecular Discovery Portfolio

research investments.

2. Progress Molecular Projects

- Apply activity-based or portfolio costing approaches to recognize multi-year, multi-

component R&D expenditures.

3. Validate Technologies and Products

- Capture regulatory and clinical trial milestones via intangible asset valuation contingent

on future adoption/partnerships.

- Employ flexible recognition of recurring profiling revenues and on-going patient

5. Monitor Clinical Outcomes

6. Periodically Review Guidance

- Revisit assumptions, costs and valuations at predefined intervals or as regulatory/clinical

evidence and applications evolve.

Overall, this framework systematically incorporates stratified medicine activities into

financial reports through consistently applied yet adaptively refined accounting principles.

Conclusion

As genomic and data technologies transform healthcare delivery, accounting standards must

evolve to transparently capture the value of molecular innovations. This paper analyzes

dynamic business models and regulatory uncertainties.

Personalized medicine refers to medical decision-making tailored to individual patient

characteristics diagnosed through genomic and molecular analysis. By integrating genomics,

clinical trials, big data and custom diagnostics, personalized medicine aims to optimize

treatment effectiveness for each patient. As these approaches mature, accounting standards

This paper examines key accounting issues in personalized medicine and proposes principles

for capturing its value. The first section provides background on emerging genomic

technologies enabling personalized strategies. Challenges involving research and

development costing, revenue recognition, and valuation are then discussed. Drawing from

these factors, an accounting framework is proposed for systematically incorporating

personalized treatments. The conclusion reflects on open areas and calls for standards

supporting continued innovation responsibly.

Advances in Genomic Technologies

Rapid advancements in genomic sequencing, molecular diagnostics, and computational

- Late 1990s: Successful mapping of the human genome provided the foundation for

exponentially to enable clinical applications.

- 2013: FDA approved first cancer drug targeting a specific gene mutation, establishing the

approval pathway for molecularly targeted therapies.

- 2015: Launch of large biobanks and datasets like UK Biobank enabled discovery of disease

subtypes and drug response biomarkers at population scale.

- 2020: Precision oncology guided by genomic profiling became standard of care for many

advanced cancers, achieving superior outcomes to one-size-fits-all chemotherapy.

These technical milestones transformed medicine by correlating genetics to drug responses at

requires consideration.

Genomic, computational and clinical research expenditures require new cost accounting as

multi-component, digital-enabled efforts yield diverse molecularly defined products/services.

Revenue Recognition

on-going care management necessitating flexible recognition approaches.

Valuation of Molecular Innovations

Genomic/omic biomarkers, diagnostic algorithms and targeted therapies represent intangible

innovations valued differently than traditional products requiring specialized metrics.

Regulatory Compliance

Evolving regulations around clinical trials, diagnostic approval pathways, and data privacy

introduce uncertainties necessitating scenario-based financial planning.

The following section proposes accounting principles addressing these factors systematically

Proposed Accounting Principles

- Apply activity-based or portfolio approaches proportionately recognizing multi-

component research spanning discovery to clinical adoption.

2. Revenue Recognition for Personalized Offerings

- Employ milestone-based or subscription recognition of genomic profiling, digital platform

access and on-going clinical management services.

- Provide transparency distinguishing recurring from one-time revenue streams to capture

value over time.

- Value intangible portfolio components based on potential for clinical adoption and

diagnostics and precision therapies.

- Quantify estimated costs of compliance scenarios and sensitivity of valuations to potential

regulatory outcomes.

5. Treatment Effectiveness Benchmarking

- Track clinical and economic outcomes transparently comparing personalized therapies to

alternative standards where available.

- Periodically benchmark against evolving evidence on treatment effectiveness and cost-

effectiveness.

By standardizing principles to systematically track value creation stages for stratified

medicines, accounting promotes transparency and responsibly paced innovation in this

emerging field.

Operationalizing Principles for Personalized Medicine Accounting

activities across personalized medicine's value chain:

research investments.

2. Progress Molecular Projects

- Apply activity-based or portfolio costing approaches to recognize multi-year, multi-

component R&D expenditures.

3. Validate Technologies and Products

- Capture regulatory and clinical trial milestones via intangible asset valuation contingent

on future adoption/partnerships.

4. Commence Commercialization

- Employ flexible recognition of recurring profiling revenues and on-going patient

Overall, this framework systematically incorporates stratified medicine activities into

financial reports through consistently applied yet adaptively refined accounting principles.

As genomic and data technologies transform healthcare delivery, accounting standards must

evolve to transparently capture the value of molecular innovations. This paper analyzes

financial reporting challenges arising from personalized medicine’s intangible R&D focus,

dynamic business models and regulatory uncertainties.

To systematically address these, new principles and an operational accounting framework

have been proposed. Continued advancement relies on accounting proactively engaging

stakeholders to refine guidance supporting responsible innovation aligned with patient

interests. Overall, evolving standards balances oversight with unlocking personalized

clinical trials, big data and custom diagnostics, personalized medicine aims to optimize

This paper examines key accounting issues in personalized medicine and proposes principles

for capturing its value. The first section provides background on emerging genomic

- Employ flexible recognition of recurring profiling revenues and on-going patient

management income streams.

5. Monitor Clinical Outcomes

- Benchmark treatment effectiveness transparently comparing outcomes and costs to

alternatives where available.

6. Periodically Review Guidance

- Revisit assumptions, costs and valuations at predefined intervals or as regulatory/clinical

evidence and applications evolve.

Overall, this framework systematically incorporates stratified medicine activities into

dynamic business models and regulatory uncertainties.

To systematically address these, new principles and an operational accounting framework

have been proposed. Continued advancement relies on accounting proactively engaging

interests. Overall, evolving standards balances oversight with unlocking personalized

medicine’s full potential for improving human welfare.

Personalized medicine refers to medical decision-making tailored to individual patient

characteristics diagnosed through genomic and molecular analysis. By integrating genomics,

clinical trials, big data and custom diagnostics, personalized medicine aims to optimize

treatment effectiveness for each patient. As these approaches mature, accounting standards

must address financial reporting implications.

This paper examines key accounting issues in personalized medicine and proposes principles

technologies enabling personalized strategies. Challenges involving research and

personalized treatments. The conclusion reflects on open areas and calls for standards

Rapid advancements in genomic sequencing, molecular diagnostics, and computational

analysis have enabled emerging personalized medicine approaches:

- Late 1990s: Successful mapping of the human genome provided the foundation for

molecular medicine applications.

- 2008: Next-generation DNA sequencing technologies launched, reducing sequencing costs

exponentially to enable clinical applications.

- 2013: FDA approved first cancer drug targeting a specific gene mutation, establishing the

individual levels, supporting tailored prevention and treatment strategies. Their accounting

requires consideration.

Accounting Challenges in Personalized Medicine

Several challenges arise in applying traditional frameworks to personalized medical

innovations:

Research and Development Costing

Genomic, computational and clinical research expenditures require new cost accounting as

multi-component, digital-enabled efforts yield diverse molecularly defined products/services.

Revenue Recognition

Unique business models emerge via clinical genomic profiling, computational platforms, and

on-going care management necessitating flexible recognition approaches.

Genomic/omic biomarkers, diagnostic algorithms and targeted therapies represent intangible

innovations valued differently than traditional products requiring specialized metrics.

The following section proposes accounting principles addressing these factors systematically

for transparent personalized medicine reporting.

Proposed Accounting Principles

1. Molecular R&D Cost Accounting

- Separately track qualifying discovery, clinical, computational and digital infrastructure

costs for intangible portfolio components.

- Apply activity-based or portfolio approaches proportionately recognizing multi-

3. Valuation of Molecular Innovations

- Value intangible portfolio components based on potential for clinical adoption and

economic benefits contingent on partnerships and regulatory approvals.

real options analyses.

4. Disclosures for Regulatory Approval Uncertainties

- Clearly discuss evolving regulations around data, clinical trials and approvals for novel

diagnostics and precision therapies.

- Quantify estimated costs of compliance scenarios and sensitivity of valuations to potential

regulatory outcomes.

5. Treatment Effectiveness Benchmarking

alternative standards where available.

effectiveness.

emerging field.

Operationalizing Principles for Personalized Medicine Accounting

To operationalize the above principles, the following framework is proposed for accounting

activities across personalized medicine's value chain:

1. Initialize Molecular Discovery Portfolio

- Configure intangible asset ledgers to track qualifying genomic, clinical and computational

research investments.

2. Progress Molecular Projects

component R&D expenditures.

management income streams.

5. Monitor Clinical Outcomes

- Benchmark treatment effectiveness transparently comparing outcomes and costs to

6. Periodically Review Guidance

- Revisit assumptions, costs and valuations at predefined intervals or as regulatory/clinical

evidence and applications evolve.

Overall, this framework systematically incorporates stratified medicine activities into

financial reports through consistently applied yet adaptively refined accounting principles.

Conclusion

evolve to transparently capture the value of molecular innovations. This paper analyzes

interests. Overall, evolving standards balances oversight with unlocking personalized

medicine’s full potential for improving human welfare.

Personalized medicine refers to medical decision-making tailored to individual patient

characteristics diagnosed through genomic and molecular analysis. By integrating genomics,

clinical trials, big data and custom diagnostics, personalized medicine aims to optimize

treatment effectiveness for each patient. As these approaches mature, accounting standards

must address financial reporting implications.

This paper examines key accounting issues in personalized medicine and proposes principles

for capturing its value. The first section provides background on emerging genomic

technologies enabling personalized strategies. Challenges involving research and

these factors, an accounting framework is proposed for systematically incorporating

- Late 1990s: Successful mapping of the human genome provided the foundation for

molecular medicine applications.

exponentially to enable clinical applications.

- 2013: FDA approved first cancer drug targeting a specific gene mutation, establishing the

approval pathway for molecularly targeted therapies.

- 2015: Launch of large biobanks and datasets like UK Biobank enabled discovery of disease

subtypes and drug response biomarkers at population scale.

- 2020: Precision oncology guided by genomic profiling became standard of care for many

advanced cancers, achieving superior outcomes to one-size-fits-all chemotherapy.

These technical milestones transformed medicine by correlating genetics to drug responses at

innovations:

Research and Development Costing

Genomic, computational and clinical research expenditures require new cost accounting as

multi-component, digital-enabled efforts yield diverse molecularly defined products/services.

Revenue Recognition

Unique business models emerge via clinical genomic profiling, computational platforms, and

on-going care management necessitating flexible recognition approaches.

Valuation of Molecular Innovations

Genomic/omic biomarkers, diagnostic algorithms and targeted therapies represent intangible

innovations valued differently than traditional products requiring specialized metrics.

Regulatory Compliance

Evolving regulations around clinical trials, diagnostic approval pathways, and data privacy

introduce uncertainties necessitating scenario-based financial planning.

Proposed Accounting Principles

- Separately track qualifying discovery, clinical, computational and digital infrastructure

- Apply activity-based or portfolio approaches proportionately recognizing multi-

component research spanning discovery to clinical adoption.

2. Revenue Recognition for Personalized Offerings

- Employ milestone-based or subscription recognition of genomic profiling, digital platform

access and on-going clinical management services.

- Provide transparency distinguishing recurring from one-time revenue streams to capture

value over time.

- Value intangible portfolio components based on potential for clinical adoption and

economic benefits contingent on partnerships and regulatory approvals.

- Clearly discuss evolving regulations around data, clinical trials and approvals for novel

diagnostics and precision therapies.

- Quantify estimated costs of compliance scenarios and sensitivity of valuations to potential

regulatory outcomes.

5. Treatment Effectiveness Benchmarking

- Track clinical and economic outcomes transparently comparing personalized therapies to

alternative standards where available.

effectiveness.

To operationalize the above principles, the following framework is proposed for accounting

activities across personalized medicine's value chain:

1. Initialize Molecular Discovery Portfolio

research investments.

2. Progress Molecular Projects

- Apply activity-based or portfolio costing approaches to recognize multi-year, multi-

component R&D expenditures.

3. Validate Technologies and Products

- Capture regulatory and clinical trial milestones via intangible asset valuation contingent

on future adoption/partnerships.

- Employ flexible recognition of recurring profiling revenues and on-going patient

5. Monitor Clinical Outcomes

6. Periodically Review Guidance

- Revisit assumptions, costs and valuations at predefined intervals or as regulatory/clinical

evidence and applications evolve.

Overall, this framework systematically incorporates stratified medicine activities into

financial reports through consistently applied yet adaptively refined accounting principles.

Conclusion

As genomic and data technologies transform healthcare delivery, accounting standards must

evolve to transparently capture the value of molecular innovations. This paper analyzes

dynamic business models and regulatory uncertainties.